Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores

Zhou Kexun; Jiang Chenlu; Li Qiu

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores

【24h】

Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores

机译：不同PD-L1肿瘤比例分数的非小细胞肺癌中Pembrolizumab单药治疗和化疗的成本效果分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives: This study aimed to assess the cost-effectiveness of pembrolizumab monotherapy compared with chemotherapy as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with different tumor proportion scores (TPS), from perspectives of payers in China.

机译：目的：本研究旨在评估Pembrolizumab单药治疗的成本效益与化疗，作为局部晚期或转移性非小细胞肺癌（NSCLC）具有不同肿瘤比例评分（TPS）的一线治疗，从视角下中国的付款人。

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer》 |2019年第2019期|共4页
作者
Zhou Kexun; Jiang Chenlu; Li Qiu;
展开▼
作者单位

Sichuan Univ West China Hosp Dept Med Oncol Canc Ctr 37 GuoXue Xiang Chengdu Sichuan Peoples;

Sichuan Anticanc Assoc Dept Org 37 ChangShou South Rd Chengdu Sichuan Peoples R China;

Sichuan Univ West China Hosp Dept Med Oncol Canc Ctr 37 GuoXue Xiang Chengdu Sichuan Peoples;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Cost-effectiveness; None-small-cell lung cancer; Pembrolizumab; Tumor proportion score;

机译：成本效益;无小细胞肺癌;Pembrozumab;肿瘤比例得分;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores [J] . Zhou Kexun, Jiang Chenlu, Li Qiu Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019,第期

机译：不同PD-L1肿瘤比例分数的非小细胞肺癌中Pembrolizumab单药治疗和化疗的成本效果分析
2. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater [J] . Reck Martin, Rodriguez-Abreu Delvys, Robinson Andrew G., Journal of Clinical Oncology . 2019,第7期

机译：keynote-024的更新分析：Pembrozumab与铂族化疗，用于高级非小细胞肺癌，PD-L1肿瘤比例分数为50％或更高
3. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater [J] . Longjiang She, Huabin Hu, Mengting Liao, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019,第期

机译：PEMBROLIZUMAB与化疗的成本效果分析作为局部晚期或转移性非小细胞肺癌的一线治疗，PD-L1肿瘤比例得分1％或更大
4. Automated Tumor Proportion Scoring for Assessment of PD-L1 Expression Based on Multi-Stage Ensemble Strategy [C] . Yuxin Kang, Hansheng Li, Xin Han, International Workshop on Machine Learning in Medical Imaging;International Conference on Medical Image Computing and Computer-Assisted Intervention . 2020

机译：基于多阶段集合策略的PD-L1表达评估自动肿瘤比例
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50: real-world data [O] . Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, 2021

机译：Pembrolizumab作为单一疗法或与铂族化疗组合在先进的非小细胞肺癌中具有PD-L1肿瘤比分（TPS）≥50％：现实世界数据
7. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50: real-world data [O] . Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, 2021

机译：Pembrolizumab作为单一疗法或与铂族化疗组合在先进的非小细胞肺癌中，具有PD-L1肿瘤比分（TPS）≥50％：现实世界数据

Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores

摘要

著录项

相似文献

相关主题

期刊订阅